Dermata Therapeutics
DRMA
6 hedge funds and large institutions have $185K invested in Dermata Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
68% more capital invested
Capital invested by funds: $110K → $185K (+$74.7K)
0.04% more ownership
Funds ownership: 0.02% → 0.06% (+0.04%)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$157K |
| 2 |
VF
Virtu Financial
New York
|
+$9.75K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$975 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$14.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$11.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$139 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $133K | +$157K | +1,453 | New |
|
|
2
Acadian Asset Management
Boston,
Massachusetts
| $32K | -$14.7K | -136 | -27% |
|
|
VF
3
Virtu Financial
New York
| $8K | +$9.75K | +90 | New |
|
4
Geode Capital Management
Boston,
Massachusetts
| $7.46K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $3.92K | +$975 | +9 | +26% |
|
6
Wells Fargo
San Francisco,
California
| $429 | – | – | – |
|
|
TSS
7
Two Sigma Securities
New York
| – | -$11.8K | -74 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$139 | -1 | Closed |
|
DRMA Hedge Fund Activity: Q4 2023 in Review
6 of the 6,863 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q4 2023, worth a combined $185K — up 68% from $110K a quarter earlier.
Fund positioning in DRMA was balanced in Q4 2023: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $157K. The largest seller was Acadian Asset Management, cutting an estimated $14.7K.
- 6 institutional investors held Dermata Therapeutics (DRMA) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $185K of Dermata Therapeutics stock for Q4 2023, up 68% quarter-over-quarter.
- 2 funds opened new Dermata Therapeutics positions in Q4 2023 and 2 closed out, a net change of 0 holders.
- The largest Dermata Therapeutics buyer in Q4 2023 was Armistice Capital, an estimated $157K added.
- The largest Dermata Therapeutics seller in Q4 2023 was Acadian Asset Management, an estimated $14.7K sold.
Based on aggregated 13F filings for Q4 2023.